What phase is the mRNA-4200 trial in?

The trial is in phase 1, and the first U.S. participant has been dosed.

How is mRNA-4200 different from personalized cancer vaccines?

mRNA-4200 is off-the-shelf and does not require customization, whereas personalized vaccines are tailored to each patient's tumor mutations.

Has Merck announced a launch date for mRNA-4200?

No launch date has been announced, as clinical trials are still in early stages.

Merck Doses First Patient in Phase 1 mRNA Cancer Therapy Trial

Merck & Co. (MRK) has dosed the first U.S. participant in a phase 1 trial of mRNA-4200, an off-the-shelf immunotherapy candidate, expanding its cancer pipeline beyond personalized vaccines.

July 17, 2026

2 min read

Source: Zacks

Merck & Co. (NYSE: MRK) has dosed the first U.S. participant in a phase 1 study of mRNA-4200, a novel off-the-shelf immunotherapy for cancer, according to a report from Zacks.

The Product

mRNA-4200 is an mRNA-based immunotherapy designed to stimulate the immune system to attack cancer cells. Unlike personalized vaccines, it is off-the-shelf, meaning it does not require customization for each patient, potentially speeding up manufacturing and distribution.

Pricing and Availability

Pricing information is not yet available, as the therapy is still in phase 1 clinical trials. The trial is expected to take several years before potential market entry.

Competition

Merck faces competition from other companies developing mRNA-based immunotherapies, such as Moderna and BioNTech. However, Merck's focus on off-the-shelf therapies targets a less crowded space.

Potential Impact on the Company

If mRNA-4200 proves effective, it could expand Merck's oncology portfolio beyond its blockbuster drug Keytruda, creating a new revenue stream. However, results are still years away, and clinical trials carry inherent risks of failure.

Frequently Asked Questions

mRNA-4200 is an mRNA-based immunotherapy from Merck designed to treat cancer, and it is off-the-shelf, meaning it does not require customization for each patient.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.